Pacira Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Pacira BioSciences, Inc. reported a return to net income in Q3 2025, driven by increased product sales and favorable legal outcomes, alongside strategic acquisitions and pipeline advancements.
NASDAQ
Pacira BioSciences reports a net loss for Q2 2025 due to investment impairment and restructuring charges, despite increased revenues.
NASDAQ
Pacira BioSciences reports a slight revenue increase in Q1 2025, driven by EXPAREL, and finalizes the acquisition of GQ Bio Therapeutics.
NASDAQ
10-Q: Pacira BioSciences Reports Q3 2024 Results, Faces Patent Setback and Records Goodwill Impairment
Pacira BioSciences reported its Q3 2024 results, which included a goodwill impairment charge and a patent invalidation, alongside a modest revenue increase.
NASDAQ
10-Q: Pacira BioSciences Reports Q2 2024 Results, Highlights Revenue Growth and Strategic Financial Moves
Pacira BioSciences announced its second quarter 2024 results, showcasing revenue growth and strategic financial activities including a debt offering and share repurchase program.
NASDAQ
Pacira BioSciences reported a 4% increase in total revenue for the first quarter of 2024, driven by growth in product sales, while also undergoing a strategic restructuring.